For more than a decade, the medical community, public health officials, and patients have been locked in a complicated debate: Should men with no symptoms routinely take the Prostate-Specific Antigen (PSA) blood test?

Back in 2013, the gold-standard independent research network, Cochrane, looked at all available data and concluded that there wasn’t sufficient evidence to prove that widespread PSA screening actually saved lives. Because PSA testing carries a heavy risk of "overdiagnosis" (finding tiny, slow-growing cancers that would never have caused harm) and subsequent overtreatment, the advice was often cautious, discouraging a blanket endorsement.

But science evolves. Armed with longer tracking windows and data from nearly 800,000 men, the newly updated 2026 Cochrane Systematic Review reveals a critical shift in the evidence.

What the New Evidence Tells Us

The review team—led by Dr. Juan VA Franco and Dr. Philipp Dahm—analyzed data across six large-scale clinical trials in Europe and North America. Thanks to decades of patient follow-up (up to 23 years in some cases), a clearer long-term picture has finally emerged.

Here are the key takeaways from the updated findings:

• A Modest but Proven Shift in Survival: For the first time, researchers can say with moderate certainty that PSA screening does reduce the risk of dying from prostate cancer.
• The Numbers: The data shows that screening reduces prostate cancer deaths by about 2 out of every 1,000 men screened. Framed another way, roughly 500 men need to be invited for regular screening to prevent one death from prostate cancer.
• Metastatic Cancer Reduction: The screening also appears to reduce the risk of being diagnosed with advanced, metastatic prostate cancer (by about 5 fewer men per 1,000).

The Elephant in the Room: Overdiagnosis

Despite the good news regarding mortality, the review stresses that the core drawback of PSA testing hasn't vanished. Screening successfully finds cancer earlier, but it also casts a incredibly wide net.

Screening detected roughly 30% more prostate cancers overall compared to no screening. This means that for every 1 to 2 lives saved, about 36 additional men were diagnosed with prostate cancer—many of whom had low-grade, indolent tumors that likely would have never caused symptoms or shortened their lives.

Receiving a cancer diagnosis naturally induces anxiety and often guides patients toward aggressive treatments like surgery or radiation, which carry potential risks of erectile dysfunction, urinary incontinence, and bowel issues.

"This is not a blanket endorsement of universal screening. The decision should always be made between a patient and their doctor, with a full understanding of both the potential benefits and the very real risks"

Why Did the Conclusions Change?

Interestingly, the underlying science didn't dramatically change; rather, our patience paid off. Prostate cancer is typically a slow-moving disease. It can take 15, 20, or even 25 years for the true benefits of an early-intervention screening program to show up on a mortality chart. The previous versions of this review simply didn't have the long-term data that we have today.

Furthermore, medical technology has progressed. While the original trials primarily evaluated standard blood tests followed by immediate tissue biopsies, today's doctors have better tools to mitigate the harms of overdiagnosis. The widespread use of modern prostate MRIs and "active surveillance" (carefully monitoring slow-growing cancers rather than rushing to surgery) means a positive PSA test doesn’t mean what it used to.

The Verdict: Shared Decision-Making

As lead author Dr. Juan Franco noted upon the release of the data, this update is not a blanket endorsement for universal, mandatory screening. Instead, it provides the solid, evidence-based foundation required for a personalized conversation. It suggests that for a well-informed individual with a good life expectancy who understands both the benefits (saving a life) and the risks (overdiagnosis and potential treatment side effects), screening is a highly reasonable choice.

Read the Full Review

 If you want to dive deeper into the statistics, read the exact breakdown of the trials, or share the hard data with your own doctor, we highly recommend reading the full, independent study.

🔗 Read the full updated report on the Cochrane Library here Cochrane Review: Prostate-specific antigen (PSA) test for prostate cancer screening